A Partnership of Excellence

A History of Nobivac®

Through Merck Animal Health, Nobivac® has made significant contributions to the development and innovation of vaccines – enabling essential progress for animal health over the decades.

1998

First company to develop a feline Bb
vaccine with Nobivac^® Feline-Bb

2003

First to introduce Advanced Delivery
Technology (ADT) needleless vaccine
delivery to avoid accidental injection
of intranasal canine cough vaccines—
Nobivac^® Intra-Trac^® 3 ADT

2005

First USDA-approved canine distemper,
adenovirus (Hepatitis), parvovirus (DAP) vaccine with 3-year DOI—Nobivac^® Canine 3-DAPv

2006

First USDA-approved feline rhinotracheitis,
calicivirus and panleukopenia virus (HCP) vaccine with a 3-year DOI—Nobivac® Feline 3-HCP

2008

Published first data demonstrating protection with our canine range against parvovirus 2c strain

2009

First to develop a Lyme vaccine,
Nobivac^® Lyme, that induced borreliacidal
antibodies to outer surface protein C
First canine influenza (H3N8) vaccine with
Nobivac^® Canine Flu H3N8

2010

First company to provide a FeLV vaccine with
a 2-year DOI with Nobivac^® Feline 2-FeLV

First leptospirosis vaccine, Nobivac^® Lepto4, with label claims against mortality and urinary shedding caused by serovars L. canicola, L. grippotyphosa, L. icterohaemorrhagiae and L. pomona

2011

Introduced VacciPure™ filtration
advancement to Nobivac^® Lepto₄

2011

Launched first bivalent canine influenza vaccine
protecting against both CIV H3N2 and CIV H3N8
with Nobivac® Canine Flu Bivalent

2016

Nobivac® Canine Flu H3N2: the first fully licensed vaccine to protect dogs against the new canine influenza virus strain H3N2.

Nobivac® Canine Flu Bivalent: the first fully licensed vaccine to protect dogs against both known strains of canine influenza virus H3N8 and H3N2.

Nobivac® Intra-Trac Oral Bb: is the first oral Bordetella vaccine proven by a real time duration of immunity study to protect dogs for 1 year against canine cough caused by Bordetella bronchiseptica.

2019

Nobivac® EDGE^™: introduced the first 0.5 mL lepto vaccine shown effective against disease, mortality and leptospiria as well as the first 0.5 mL combo vaccine to protect against parainfluenza.